Amarin Corp Plc (AMRN)

[ggwpq]

More evidence HDL is not a good bio-marker for CVD,

http://www.forbes.com/sites/johnlamattina/2015/09/17/amgens-acquisition-of-dezima-and-cetp-drug-like-pfizers-03-buy-of-esperion-will-history-repeat/

"Pfizer ran a cardiovascular outcomes trial (CVOT) comparing torcetrapib + Lipitor to Lipitor alone in order to demonstrate that the unprecedented LDL-cholesterol (LDL-C) lowering and HDL-C effects of the combination translated to far fewer heart attacks and strokes than seen with Lipitor alone. Shockingly, this CVOT, known as ILLUMINATE, showed that the combination was inferior to Lipitor alone."

So I think Kiwi's worry of R-IT not having enough patients with low HDL is misplaced.